Inside information, profit warning: Nightingale Health continues to grow but will not reach its 50% growth target this financial year as about EUR 2 million of revenue shifts to next financial year

The previously communicated target of more than 50% revenue growth for the current financial year will not be reached because the timeline of a major project has shifted for reasons outside the company's control. The project will proceed and be implemented in full scope. The associated revenue, approximately EUR 2 million, will be recognised in the next financial year rather than the current one. This is a shift in timing, not a change to the project or its total value.

Despite the approximately EUR 2 million of project revenue shifting to the next financial year, Nightingale Health still expects current-year revenue to grow by approximately 20% (+/- 5%) compared with the previous financial year. Had the postponed project revenue been recognised in the current financial year as originally planned, the company would have reached revenue growth of approximately 65%. Over the year, Nightingale Health has continued strong sales efforts across both its healthcare and research businesses.

Nightingale Health expects revenue to exceed EUR 10 million in the next financial year. The company will announce more detailed targets for the financial year 2026–2027 as part of its full-year result release in September 2026.

"Not reaching this year's growth target is disappointing, but the reason is timing, not lost business. The project will be delivered in full and the majority of its revenue moves with it into next financial year, while our healthcare and research businesses have continued to grow strongly. We enter the next financial year with real momentum," says Teemu Suna, CEO and Founder of Nightingale Health.